Access to non-registered medicines is fast-moving. One of the options for access is through a compassionate use programme. In this session, we look at recent adjustments to national compassionate use policies and their impact on healthcare professionals, industry and patients: What are the key changes and implications of these adjustments? From policy, practice and industry perspectives, we reflect on the opportunities and dilemmas within this changing landscape. In doing so, we explore how compassionate use can be future-proofed, keeping in mind scientific and technological developments. This session provides space for exchange, insight and discussion - for anyone interested in patient access to non-registered medicines through compassionate use programmes.

Chairs: Stefan Verweij (CBG | MEB), Yvette Schipper (RSNN & Lygature), Sophie Huiskens (Lygature)

Speakers: Eugenie van Lieshout (Johnson & Johnson)

FIGON Partners: Lygature, RSNN